Recognition and management of oral mucosal injury caused by mammalian target of rapamycin inhibitors: A case series

Case Reports in Oncology

Volumn 8, Issue , 2015, Pages 369-377

  Meiller, Timothy F ^a   Varlotta, Sharon ^a   Weikel, Dianna ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

Mammalian target of rapamycin inhibitors; Management; Recognition; Stomatitis

Indexed keywords

CLOBETASOL; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; EVEROLIMUS; LETROZOLE; RAPAMYCIN; STEROID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CASE REPORT; CASE STUDY; CORTICOSTEROID THERAPY; DRUG RESPONSE; DRUG WITHDRAWAL; EARLY INTERVENTION; ELIXIR; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LOWER LIP; MALE; MIDDLE AGED; MOUTH INJURY; MOUTH ULCER; OINTMENT; ORAL MUCOSAL DISEASE; ORAL MUCOSAL INJURY; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; TONGUE ULCER; TOPICAL TREATMENT;

EID: 84941947870     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000438747     Document Type: Article

References (15)

1. Ponticelli C. The pros and the cons of mTOR inhibitors in kidney transplantation. Expert Rev Clin Immunol. 2014; 10: 295-230.
2. Gomez-Pinillos A, Ferrari AC. mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am. 2012; 26: 483-505.
3. Wyeth Pharmaceuticals: Rapamune (sirolimus) oral solution and tablets (package insert). Philadelphia, Wyeth Pharmaceuticals, 2015.
4. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-2281.
5. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006; 5: 671-688.
6. Wyeth Pharmaceuticals: Torisel Kit (temsirolimus) injection, for intravenous infusion only (package insert). Philadelphia, Wyeth Pharmaceuticals, 2015.
7. Novartis Pharmaceuticals Corporation: Afinitor (everolimus) tablets for oral administration. Afinitor Disperz (everolimus tablets for oral suspension) (package insert). Hanover, Novartis Pharmaceuticals Corporation, 2015.
8. Tsang CK, Qi H, Liu LF, et al. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today. 2007; 12: 112-124.
9. Sonis ST. Oral mucositis. Anticancer Drugs. 2011; 22: 607-612.
10. Sonis S, Treister N, Chawla S, et al. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010; 116: 210-215.
11. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013; 63: 249-279.
12. Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando) 2014; 28: 126-133.
13. Preeti L, Magesh K, Rajkumar K, et al. Recurrent aphthous stomatitis. J Oral Maxillofac Pathol. 2011; 15: 252-256.
14. Chuang P, Langone AJ. Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. Am J Transplant. 2007; 7: 714-717.
15. de Oliveira MA, Martins E, Martins F, Wang Q, et al. Clinical presentation and management of mTOR inhibitor-Associated stomatitis. Oral Oncol. 2011; 47: 998-1003.